한빛사논문
- 조회379
Ja-Hyun Koo,1,2,6 Gil-Ran Kim,1,6 Kyung-Ho Nam,1 and Je-Min Choi1,3,4,5,*
1Department of Life Science, College of Natural Sciences, Hanyang University, Seoul 04763, Republic of Korea
2The Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139, USA
3Research Institute for Natural Sciences, Hanyang University, Seoul 04763, Republic of Korea
4Research Institute for Convergence of Basic Sciences, Hanyang University, Seoul 04763, Republic of Korea
5Hanyang Institute of Bioscience and Biotechnology, Hanyang University, Seoul 04763, Republic of Korea
6Equal contributions
*Corresponding author.
Abstract
With the advent of cancer immunotherapy, immunomodulation has emerged as an important strategy for the treatment of various diseases. We review recent advances in clinical trials of cell-penetrating peptide (CPP) applications for immunotherapy and also discuss their challenges and opportunities for preclinical studies in various immune diseases. CPP conjugation to antigenic peptides or proteins can enable efficient antigen uptake and cross-presentation by antigen-presenting cells (APCs), which induce both humoral and cytotoxic responses. In addition, CPP-coupled immune modulators can enhance antitumor immunity or anti-inflammatory effects to regulate allergies and autoimmunity. Given their huge advantages in overcoming delivery barriers, CPP-based strategies for immunomodulation could extend drug optimization and advance immunotherapy in various human diseases.
논문정보
- Review Paper
- 2022년 04월 (BRIC 등록일 2022-05-03)
- 국내 연구진
- 생명과학 > 면역학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
